Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2012, 21(6):493-501

Diabetes and heart failure

Murín J
I. interná klinika LFUK a UN Bratislava, nemocnica Staré mesto

Diabetes mellitus and heart failure are nowadays both diseases having epidemic characteristics. Diabetes seems to be an engine of heart failure development. More severe heart failure forms show more frequently the presence of diabetes. This is true for both systolic and diastolic heart failure types. In the pathophysiology of heart failure in diabetics there is an influence of myocardial ischaemia, of metabolic (lipidic and diabetic) serum changes and of diabetic cardiomyopathy. Also activation of the reninangiotensin-aldosterone system is important: mainly the alternative pathway where enhanced activity of ACE-2 enzyme seems to be present. The author presents here clinical signs of heart failure and also the management of heart failure in diabetics. He discusses the problem of strict versus normal control of serum glycaemia, and also the pharmacological treatment of diabetes, mostly from the safety point of view. The topic is important for clinical practice and points to the management of heart failure in diabetics. Prevention is here better than treatment.

Keywords: diabetes mellitus; heart failure; diabetic cardiomyopathy; antidiabetics

Published: June 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Murín J. Diabetes and heart failure. Cardiology Letters. 2012;21(6):493-501.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mokáň M, Galajda P, Prídavková D, et al. Prevalencia diabetes mellitus a metabolického syndrómu na Slovensku. Diabetes a obezita 2006;12:10-17.
    2. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29-34. Go to original source...
    3. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular health study. J Am Coll Cardiol 2000;35:1628-1637. Go to original source...
    4. Nichols GA,Hillier TA, Erbey JR, et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001;24:1614-1619. Go to original source...
    5. Arnold JM, Yusuf S, Young J, et al. Prevention of heart failure in patients in the heart outcomes prevention evaluation (HOPE) study. Circulation 2003;107:1284-1290. Go to original source...
    6. MERIT - HF Investigators. Effect of metoprolol CR/XL in chronic heart failure. Lancet 1999;353:2001-2007. Go to original source...
    7. Poole - Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European trial (COMET). Lancet 2003;362:7-13. Go to original source...
    8. Cohn JN, Tognoni A. A randomized trial of the angiotensin - receptor blocker valsartan in chronic heart failure. N Engl. J Med 2001;345:1667-1675. Go to original source...
    9. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103:2668-2673. Go to original source...
    10. Held C, Gerstein HC, Yusuf S, et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007;115:1371-1375. Go to original source...
    11. Jaffe AS, Spadaro JJ, Schechtman K, et al. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984;108:31-37. Go to original source...
    12. Aguilar D, Solomon SD, Kober L, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004;110:1572-1578. Go to original source...
    13. Das SR, Drazner MH, Yancy CW, et al. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the studies of left ventricular dysfunction (SOLVD) prevention trial. Am Heart J; 2004;148:883-888. Go to original source...
    14. Domanski M, Krause-Steinrauf H, Deedwania P, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2003;42:914-922. Go to original source...
    15. From AM, Leibson CL, Bursi F, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 2006;119:591-599. Go to original source...
    16. Hellerman JP, Jacobsen SJ, Gersh BJ, et al. Heart failure after myocardial infarction: a review. Am J Med 2002;113:324-330. Go to original source...
    17. Gustaffson I, Brendorp B, Seibaek M, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 2004;43:771-777. Go to original source...
    18. Pijna IL, Buchter C. Heart failure in women. Cardiol Rev 2003;11:337-344. Go to original source...
    19. Murarka S, Movahed MR. Diabetic cardiomyopathy. J Card Fail 2010;16:971-979. Go to original source...
    20. Saunders J, Mathewkutty S, Drazner MH, MGuire DK. Cardiomyopathy in type 2 diabetes: update on pathophysiological mechanisms. Herz 2008;33:184-190. Go to original source...
    21. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009;53:S35-S42. Go to original source...
    22. Rask-Madsen C, King GL. Mechanisms of disease: Endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007;3:46-56. Go to original source...
    23. Khera A, Mc Guire DK. Management of diabetic dyslipidemia: need for reappraisal of the goals. Am J Cardiovasc Drugs 2005;5:83-91. Go to original source...
    24. Mathewkutty S, McGuire DK. Platelet perturbations in diabetes: Implications for cardiovascular disease risk and treatment. Expert Rev Cardiovasc Ther 2009;7:541-549. Go to original source...
    25. Libby P, Plutzky J. Inflammation in diabetes mellitus: Role of peroxisome proliferator-activated receptor alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol 2007;99:27B-40B. Go to original source...
    26. Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for advanced glycation end-poducts (RAGE). Cardiovascular implications. Diab Vasc Dis Res 2009;6:7-14. Go to original source...
    27. Bertoni AG, Tsai A, Kasper EK, et al. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 2003;26:2791-2795. Go to original source...
    28. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007;116:434-448. Go to original source...
    29. Poormina IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circulation 2006;98:596-605. Go to original source...
    30. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115:3213-3223. Go to original source...
    31. Rubler S, Dlugash J, Yuceoglu YZ, et al. A new type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595-602. Go to original source...
    32. Masoudi FA, Inzucchi SE. Diabetes mellitus and heart failure: epidemiology, mechanisms and pharmacotherapy. Am J Cardiol 2006;99(suppl. 1):113-132. Go to original source...
    33. Du X, Matsumura T, Edelstein D, et al. Inhibition ob GAPDH activity by (ADP- ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003;112:1049-1057. Go to original source...
    34. Cai L, Wang Y, Zhou G, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 2006;48:1688- 1697. Go to original source...
    35. Wang J, Song Y, El-Sherif L.et al. Cardiac metallothionein induction plays the major roll in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 2006;113:544-554. Go to original source...
    36. Kass DA. Getting better without AGE: new insights into the diabetic heart. Circ Res 2003;92:704-706. Go to original source...
    37. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003;21:3-12. Go to original source...
    38. Cerami A, Vlassara H, Brownlee M. Role of advanced glycosylation products in complications of diabetes. Diabetes Care 1988;11(Suppl 1):73-79.
    39. Cesario DA, Braz R, Shivkumar K. Alterations in ion channel physiology in diabetic cardiomyopathy. Endocrinol Metab Clin Nort Amer 2006;35:601- 610. Go to original source...
    40. Yan SF, Ramasamy R, Naka Y, et al. Glycation, inflammation and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003;93:1159-1169. Go to original source...
    41. Lim SH, Mac Fayden RJ, Lip GYH. Diabetes mellitus, the reninangiotensin-aldosterone system and the heart. Arch Intern Med 2004;164:1737-1748. Go to original source...
    42. Lin X, Wang J, Takeda N, et al. Changes in cardiac protein kinase C activities and isoenzymes in streptozotocin-induced diabetes. Am J Physiol 1999;277:E798-E804. Go to original source...
    43. Noguchi T, Hunlich M, Camp PC, et al. Thin filament-based modulation of contractile performance in human heart failure. Circulation 2004;110:982- 987. Go to original source...
    44. Braz JC, Gregory K, Pathak A, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 2004;10:248-254. Go to original source...
    45. Shigegawa M, Katanosaka Y, Wakabayashi S. Regulation of the cardiac Na+/Ca+2 exchanger by calcineurin and protein kinase C. Ann NY Acad Sci 2007;1099:53-63. Go to original source...
    46. Flesch M, Margulies KB, Mochmann HC, et al. Differential regulation of mitogen-activated protein kinases in the failing human heart in response to mechanical unloading. Circulation 2001;104:2273-227 Go to original source...
    47. An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006;291:H1489-504. Go to original source...
    48. Zhburn YT, Grayburn P, Karim A. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000;97:1784-1789. Go to original source...
    49. Barouch LA, Berkowitz DE, Harrison RW, et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003;108:754-759. Go to original source...
    50. Kuethe F, Sigusch HH, Bornstein SR, et al. Apoptosis in patients with dilated cardiomyopathy and diabetes: a feature of diabetic cardiomyopathy? Horm Metab Res 2007;39:672-676. Go to original source...
    51. Iacobellis G, Ribando MC, Zappaterreno A, et al. Relationship of insulin sensitivity and left ventricular mass in uncomplicated obesity. Obes Res 2003;11:518-524. Go to original source...
    52. Morisco C, Condorelli G, Trimarco V, et al. Akt mediates the crosstalk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res 2005;96:180-188. Go to original source...
    53. Wang CC, Goalstone ML, Drazuin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 2004;53:2735-2740. Go to original source...
    54. Villarreal FJ, Kim NN, Ungab GD, et al. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 1993;88:2849-2861. Go to original source...
    55. Dostal DE, Baker KN. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999;85:643-650. Go to original source...
    56. Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1955;91:2573-2581. Go to original source...
    57. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-776. Go to original source...
    58. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000;275:33 238-33 243. Go to original source...
    59. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts antiotensin I to angiotensin 1-9. Circ Res 2000;87:E1-E9. Go to original source...
    60. Huentelman MJ, Grobe JL, Vazquez J, et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 2005;90:783790. Go to original source...
    61. Der Sarkissian S, Grobe JL, Yuan L, et al. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 2008;51:712-718. Go to original source...
    62. Kim MA, Yang D, Kida K, et al. Effects of ACE2 inhibition in the post-myocardial infarction heart. J Card Fail 2010;16:777785. Go to original source...
    63. Dong B, Yu QT, Dai HY, et al. Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy. J Am Coll Cardiol 2012;59:739-747. Go to original source...
    64. Jessup M, Greenberg B, Mancini D, et al., for the Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011;124:304-313. Go to original source...
    65. Aasum E, Hafstad AD, Severson DL, et al. Age-dependent changes in metabolism, contractile function and ischemic sensitivity in hearts from db/db mice. Diabetes 2003;52:434-441. Go to original source...
    66. Lacombe VA, Viachenko-Karpinski S, Terentyev D, et al. Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes. Am J Physiol Regul Integr Comp Physiol 2007;293:R1787-R1797. Go to original source...
    67. Joffe II, Travers KE, Perreault-Micale CL, et al. Abnormal cardiac function in the streptozotocin - induced non-insulin-dependent diabetic rat: noninvasive assessment with Doppler echocardiography and contribution of the nitric oxide pathway. J Am Coll Cardiol 1999;34:2111-2119.68. Belky DD, Swanson EH, Dillmann WH. Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 2004;53:3201-3208. Go to original source...
    68. Vasanji Z, Cantor EJF, Juric D, et al. Alterations in cardiac contractile performance and sarcoplasmic reticulum function in sucrose - fed rats is associated with insulin resistance. Am J Physiol Cell Physiol 2006;291:C772-C780. Go to original source...
    69. Rao VU, Spinale FG. Controlling myocardial matrix remodelling: implications for heart failure. Cardiol Rev 1999;7:136-143. Go to original source...
    70. Asbun J, Villareal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006;47:693-700. Go to original source...
    71. Mulieri LA, Leavitt BJ, Hasenfuss G, et al. Contraction frequency dependence of twitch and diastolic tension in human dilated cardiomyopathy. Basic Res Cardiol 1992;87(suppl 1):199-212. Go to original source...
    72. Szczepaniak LS, Victor RG, Orci L, et al. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res 2007;101:759-767. Go to original source...
    73. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by doppler echocardiography. J Am Coll Cardiol 2006;48:1548-1551. Go to original source...
    74. Poirier P, Bogaty P, Philippon F, et al. Preclinical diabetic cardiomyopathy: relation of left ventricular diastolic dysfunction to cardiac autonomic neuropathy in men with uncomplicated wellcontrolled type 2 diabetes. Metabolism 2003;52:1056-1061. Go to original source...
    75. Diamant M, Lamb HJ, Groeneveld Y, et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003;42:328-335. Go to original source...
    76. Berg TJ, Snorgaard O, Faber J, et al. Serum levels of advanced glycation end-products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 1999;22:1186-1190. Go to original source...
    77. Bertoni AG, Goff DC jr, D´Agostino RB jr. Diabetic cardiomyopathy and subclinical cardiovascular disease: the: multi-ethnic study of atherosclerosis (MESA). Diabetes Care 2006;29:588-594. Go to original source...
    78. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and Treatment of acute and chronic heart failure 2012. Eur J Heart Fail 2012;14:803-869. Go to original source...
    79. Swedberg K, Komajda M, Boehm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885. Go to original source...
    80. Packer M, Coats AJ, Fowler MF, et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl J Med 2001;344:1651-1658. Go to original source...
    81. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717. Go to original source...
    82. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321. Go to original source...
    83. UK Prospective Diabetes Study Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS). Lancet 1998;352:854865. Go to original source...
    84. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572. Go to original source...
    85. The Action to Control CardiOvascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2553. Go to original source...
    86. Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J 2006;151:91-98. Go to original source...
    87. Nichols GA, Koro CE, Gullion CM, et al. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 2005;21:51-57. Go to original source...
    88. Smoke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005;149:168-174. Go to original source...
    89. Massoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin and outcomes in older patients with diabetes and heart failure. Circulation 2005;111:583-590. Go to original source...
    90. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471. Go to original source...
    91. Komajda M, McMurray JJV, Beck-Nielsen, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010;31:824-831. Go to original source...

    Return to the content